RLF-100 or Aviptadil
- RLF-100 is being probed to treat Covid-19 patients as initial studies have shown that the drug is able to halt SARS-CoV-2 virus replication in lungs.
- RLF-100 or Aviptadil is a formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP).
- VIP is released throughout the body, but remains mostly concentrated in lungs.
- It is produced by immune cells and nerve endings and acts as a neurotransmitter.
- It helps improve muscle activity and blood flow in gastrointestinal tract.
- VIP has anti-inflammatory and anti-cytokine activity properties.
- It protects alveolar type II cells responsible for oxygen exchange in lungs.
- Since coronavirus attacks lungs and the alveolar cells, drug may be helpful in preventing SARS-CoV-2 onslaught in alveolar cell and limit damage in lung.
.PNG)
